Logo for Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Investor Relations Material

Latest events

Logo for Supernus Pharmaceuticals Inc

Status Update

Supernus Pharmaceuticals
Logo for Supernus Pharmaceuticals

Status Update

23 May, 2024
Logo for Supernus Pharmaceuticals

Q1 2024

8 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Supernus Pharmaceuticals Inc

Access all reports
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its lead product candidate is Duopa (levodopa-carbidopa intestinal gel), a combination of levodopa and carbidopa for the treatment of Parkinson's disease in adults experiencing end-of-dose wearing off and end-of-dose dyskinesia; and ondansetron hydrochloride injectable suspension, which is being developed as a potential next generation form of treatment for chemotherapy-induced nausea and vomiting.